What plant does quillaic acid come from?

Quillaic acid is the primary triterpenoid aglycone isolated from Quillaja saponaria, commonly called the soapbark or soap tree, native to Chile and Peru. It is released when the glycosidic bonds of quillaja saponins are hydrolyzed, exposing the pentacyclic oleanane-type core structure responsible for much of the compound's bioactivity.

Is quillaic acid the same as quillaja saponin?

No, quillaic acid is the aglycone (sugar-free core) of quillaja saponins, meaning it is the triterpenoid backbone that remains after hydrolysis removes the attached sugar chains. Quillaja saponins are the intact glycoside molecules used commercially in food emulsification and vaccine adjuvants (such as QS-21), while quillaic acid represents the isolated bioactive scaffold studied for direct pharmacological effects.

What is the effective dose of quillaic acid for anti-inflammatory effects?

Human dosing data does not yet exist for isolated quillaic acid. In rodent studies, antinociceptive and anti-inflammatory effects have been observed at intraperitoneal doses of approximately 10–100 mg/kg body weight. Translating these figures to human oral supplementation is not currently validated, and no standardized supplement dosage has been established by regulatory or clinical bodies.

Can quillaic acid boost the immune system?

Quillaic acid has shown immunomodulatory activity in vitro by influencing macrophage activation and cytokine profiles, including potential suppression of TNF-α and IL-6 in lipopolysaccharide-stimulated cell cultures. However, whether this translates to meaningful immune enhancement or regulation in living humans remains unproven, and the compound should not currently be used as a substitute for evidence-based immune therapies.

Is quillaic acid safe to take as a supplement?

Oral safety data for isolated quillaic acid in humans is extremely limited. At high doses, quillaja-derived saponins are known to cause gastrointestinal distress and possess hemolytic potential in blood contact scenarios. Individuals on anticoagulants, immunosuppressants, or those who are pregnant should avoid use until human clinical safety trials establish a validated dosing and safety profile.

What does the research evidence show about quillaic acid's effectiveness for pain relief?

Current evidence for quillaic acid's pain-relieving effects is limited to preliminary animal studies using thermal pain models, which showed dose-dependent antinociceptive activity in mice. No human clinical trials have been conducted to date, so efficacy and optimal dosing in people remain unknown. These early-stage findings are promising but cannot yet support therapeutic claims for human pain management.

Does quillaic acid interact with common medications?

There is insufficient clinical data on potential drug interactions with quillaic acid, as human pharmacokinetic studies are lacking. Due to its surfactant properties and saponin structure, theoretical concerns exist regarding interactions with fat-soluble medications or nutrient absorption, but these have not been formally evaluated. Individuals taking prescription medications should consult a healthcare provider before supplementing with quillaic acid.

Who should avoid taking quillaic acid supplements?

Pregnant and nursing women should avoid quillaic acid due to absence of safety data in these populations. Individuals with saponin sensitivity or gastrointestinal conditions that may be affected by surfactant compounds should exercise caution. Those with compromised immune systems or taking immunosuppressant medications should consult a physician before use, given the ingredient's potential immunomodulatory properties.

Quillaic Acid

Quillaic acid is a pentacyclic triterpenoid aglycone derived primarily from Quillaja saponaria (soapbark tree) that serves as the core scaffold of quillaja saponins. It exerts anti-inflammatory and antinociceptive effects primarily through inhibition of pro-inflammatory cytokine pathways and modulation of arachidonic acid metabolism.

Category: Compound Evidence: 2/10 Tier: Emerging

Origin & History

Quillaic acid is a triterpene saponin and the major aglycone derived from Quillaja saponaria Mol., a Chilean indigenous tree commonly called the soapbark tree. The compound is typically extracted from the tree's bark and has the molecular formula C₃₀H₄₆O₅ with a molecular weight of 486.68 g/mol.

Historical & Cultural Context

Quillaic acid is derived from Quillaja saponaria, described as a Chilean indigenous tree, suggesting traditional use in indigenous medicine systems. However, specific historical applications or detailed ethnopharmacological context are not documented in the available research.

Health Benefits

• Pain relief: Demonstrated dose-dependent antinociceptive effects in murine thermal models (preliminary animal evidence only)
• Anti-inflammatory activity: Showed topical anti-inflammatory effects in animal models (preliminary evidence)
• Potential immunomodulatory effects: May modulate immune function due to saponin structure (theoretical, no clinical evidence)
• Surfactant properties: Amphiphilic nature may contribute to biological activity (mechanistic theory only)
• Traditional medicinal use: Derived from indigenous Chilean tree historically used in medicine (traditional evidence only)

How It Works

Quillaic acid inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin E2 synthesis and thereby blunting the inflammatory cascade at peripheral nociceptor sites. It also appears to suppress NF-κB signaling, reducing transcription of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. Additionally, quillaic acid may interact with TRP (transient receptor potential) channels involved in thermal pain transduction, which partially explains its antinociceptive dose-dependence observed in murine hot-plate and tail-flick models.

Scientific Research

Available evidence is limited to animal studies with no human clinical trials found. Arrau et al. (2011) demonstrated antinociceptive effects in mice (J Ethnopharmacol 2011 Jan 7;133(1):164-7), while Rodríguez-Díaz et al. (2011) reported topical anti-inflammatory activity (J Pharm Pharmacol 2011 May;63(5):718-24). No PubMed PMIDs for human studies were available in the provided research.

Clinical Summary

Human clinical data on quillaic acid as an isolated compound is currently absent; all available efficacy evidence derives from in vitro cell studies and in vivo rodent models. In murine thermal antinociception assays (hot-plate and writhing tests), quillaic acid demonstrated dose-dependent pain relief at doses ranging from approximately 10–100 mg/kg administered intraperitoneally. Topical anti-inflammatory effects were quantified using the carrageenan-induced paw edema model in mice, showing statistically significant edema reduction compared to vehicle controls. Immunomodulatory observations remain preliminary, limited to in vitro macrophage assays without validated human translational data.

Nutritional Profile

Quillaic acid is a pentacyclic triterpenoid saponin aglycone (molecular formula C30H48O5, molecular weight ~492.7 g/mol), not a conventional nutritional ingredient and therefore carries no meaningful macronutrient or micronutrient profile in the dietary sense. Key compositional facts: it is a lipophilic compound with an amphiphilic character conferred by its carboxyl group at C-28 and hydroxyl groups at C-3 and C-16, giving it surfactant behavior. It is derived primarily from the bark of Quillaja saponaria (soapbark tree), where quillaic acid serves as the aglycone backbone of the Quillaja saponins (QS-21, QS-7, etc.) at concentrations ranging approximately 2–10% of total saponin extract by dry weight depending on extraction method. Macronutrients: negligible protein, fat (as a triterpenoid it is structurally lipid-like but not a dietary fat), and carbohydrate content when in isolated aglycone form. Bioactive compound concentration: as an isolated compound it is used in microgram-to-milligram quantities in research contexts. Bioavailability: oral bioavailability is limited due to poor aqueous solubility (log P estimated ~4–5); absorption is dependent on formulation, and gut microbiota may further hydrolyze saponin precursors to release quillaic acid in situ. No established dietary reference values, RDAs, or nutritional benchmarks exist for this compound.

Preparation & Dosage

No clinically studied dosage ranges for human use are available. Commercial products contain standardized extracts with 95-99.45% purity (HPLC), but no human dosing protocols have been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other triterpene saponins, anti-inflammatory botanicals, traditional Chilean herbs, topical pain relief compounds, immunomodulatory saponins

Safety & Interactions

Quillaic acid and quillaja saponins at high oral doses can cause gastrointestinal irritation, including nausea, vomiting, and diarrhea, due to their surfactant properties disrupting intestinal mucosal membranes. Hemolytic activity has been documented in vitro, meaning intravenous administration carries risk, though oral bioavailability is generally low due to poor absorption of intact saponins. Potential interactions exist with anticoagulant drugs such as warfarin and immunosuppressants, as quillaic acid's immunomodulatory activity could theoretically alter their efficacy. Safety during pregnancy and lactation has not been established, and use is not recommended in these populations without medical supervision.